Carestream scores FDA clearance for tool to reduce radiation dosage during imaging

The U.S. Food and Drug Administration has cleared a new tool from imaging vendor Carestream that helps providers reduce radiation dosage during exams, leaders announced Tuesday.

Part of the Rochester, New York, firm’s Smart Noise Cancellation technology, the artificial intelligence-powered feature helps minimize patient exposure without hampering the quality of digital X-rays.

“This improved capability to optimize radiation dose will be especially valuable in neonatal and pediatric diagnostic imaging, where imaging at the lowest possible dose is crucial for young patients,” Ron Muscosky, worldwide product line manager, said in a Feb. 8 announcement.

Carestream said its “groundbreaking” Smart Noise Cancellation product can also improve diagnostic quality, preserve fine detail and produce better contrast-to-noise ratios for images acquired at nominal exposures. The 510(k) clearance was granted following a recent reader study comparing pairwise images taken using a typical dose versus a reduced amount utilizing noise cancellation, according to the announcement.

Marty Stempniak

Marty Stempniak has covered healthcare since 2012, with his byline appearing in the American Hospital Association's member magazine, Modern Healthcare and McKnight's. Prior to that, he wrote about village government and local business for his hometown newspaper in Oak Park, Illinois. He won a Peter Lisagor and Gold EXCEL awards in 2017 for his coverage of the opioid epidemic. 

Around the web

The new F-18 flurpiridaz radiotracer is expected to help drive cardiac PET growth, but it requires waiting between rest and stress scans. Software from MultiFunctional Imaging can help care teams combat that problem.

News of an incident is a stark reminder that healthcare workers and patients aren’t the only ones who need to be aware around MRI suites.

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.